PHARMAS CRUSHED BY THE NOVO SPELL
02/01/25 -"Pharmas closed the year with a dreadful performance, itself the reflection of dashed excessive hopes for GLP-1 developments. The unwarranted Novo Nordisk collapse on 19-12 on a marginal miss in its ..."
Pages
56
Language
English
Published on
02/01/25
You may also be interested by these reports :
27/02/26
Acciona delivered a record performance in FY25, reporting consolidated EBITDA of €3,211m — well above its €2,700-€3,000m target range. The ...
27/02/26
ENGIE reported 2025 results in line with expectations and issued new guidance through 2028, incorporating the acquisition of UK DNO UK Power Networks ...
26/02/26
Solid FY25 results fully in line with expectations, with a current NIGS of €1.6bn (+9.1%, before scope, FX, energy prices and various adjustments, ...
26/02/26
Alongside solid 2025 results, ENGIE has agreed to acquire 100% of UK Power Networks for £10.5bn equity (£15.8bn EV) from CK Group, controlled by Li ...